AdvanCell Breaks Ground on Andover, MA Manufacturing Facility for Targeted Alpha Therapies
- AdvanCell held a groundbreaking ceremony for a 128,000-square-foot U.S. headquarters and manufacturing facility in Andover, Massachusetts.
- The facility represents AdvanCell's first internal U.S. manufacturing site and will support production scaling for clinical and commercial targeted alpha therapy programs.
Operational Impact
AdvanCell's new Andover facility adds U.S.-based manufacturing capacity for targeted alpha therapies, reducing reliance on contract manufacturing for clinical and commercial supply of its pipeline programs.
Source: Contract Pharma Breaking News RSS
Resilience and Eli Lilly Expand Ohio Manufacturing Partnership With $750M Investment
- Resilience and Eli Lilly are investing $750 million combined to add KwikPen injectable-device production at Resilience's Ohio facilities, with operations launching in early 2027.
- The expansion will create at least 400 new jobs and grow Resilience's Ohio workforce to over 1,400 across two Cincinnati-region sites totaling nearly 1 million square feet.
- The multi-year partnership, begun in 2023, has already produced more than 150 million doses in vial and pre-filled syringe formats for U.S. diabetes and obesity medicines.
Operational Impact
Resilience's Ohio expansion adds domestic fill-finish and device-assembly capacity for high-volume diabetes and obesity injectables, reducing reliance on offshore CDMO partners for Lilly's critical commercial programs.
Source: PharmaSource RSS